Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years
BACKGROUND/AIMS: Liver biopsy (LB) remains the gold standard for the evaluation of liver disease. However, over the past two decades, many noninvasive tests have been developed and utilized in clinical practice as alternatives to LB. The aim of this study was to evaluate the clinical use and safety of LB in the era of noninvasive assessment of liver fibrosis.
METHODS: This retrospective study included 1,944 consecutive cases of LB performed between 2001 and 2018 in a tertiary hospital. All of the LBs were conducted under ultrasonography guidance with 18-gauge cutting needles.
RESULTS: LBs were performed an average of approximately 108 times per year during the study period. Chronic hepatitis B (25.3%) and suspected malignancy (20.5%) were the two most common indications for LB. The use of LB for nonalcoholic fatty liver disease increased from 8.1% to 17.2% in the past 5 years compared to the last 10 years, while that for viral hepatitis decreased from 40.3% to 18.9%. Discordance rate between the suspected diagnosis and the final diagnosis was 2.6% (51 cases). The overall rate of major adverse events was 0.05% (one case), which involved delayed bleeding at the biopsy site. Liver cirrhosis was observed in 563 cases (28.9%), and the presence of cirrhosis did not affect the frequency of complications (P=0.289).
CONCLUSION: LB is widely used in clinical practice as an irreplaceable diagnostic tool, even in the era of noninvasiveness. Ultrasonography-guided LB can be performed safely in patients with liver cirrhosis.
Errataetall: |
CommentIn: Clin Mol Hepatol. 2020 Jul;26(3):302-304. - PMID 32646204 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
---|---|
Enthalten in: |
Clinical and molecular hepatology - 26(2020), 3 vom: 25. Juli, Seite 318-327 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Chang, Young [VerfasserIn] |
---|
Links: |
---|
Themen: |
Complication |
---|
Anmerkungen: |
Date Completed 23.06.2021 Date Revised 23.06.2021 published: Print-Electronic CommentIn: Clin Mol Hepatol. 2020 Jul;26(3):302-304. - PMID 32646204 Citation Status MEDLINE |
---|
doi: |
10.3350/cmh.2019.0019n |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM310300525 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM310300525 | ||
003 | DE-627 | ||
005 | 20231225135810.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3350/cmh.2019.0019n |2 doi | |
028 | 5 | 2 | |a pubmed24n1034.xml |
035 | |a (DE-627)NLM310300525 | ||
035 | |a (NLM)32447878 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Chang, Young |e verfasserin |4 aut | |
245 | 1 | 0 | |a Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 23.06.2021 | ||
500 | |a Date Revised 23.06.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a CommentIn: Clin Mol Hepatol. 2020 Jul;26(3):302-304. - PMID 32646204 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND/AIMS: Liver biopsy (LB) remains the gold standard for the evaluation of liver disease. However, over the past two decades, many noninvasive tests have been developed and utilized in clinical practice as alternatives to LB. The aim of this study was to evaluate the clinical use and safety of LB in the era of noninvasive assessment of liver fibrosis | ||
520 | |a METHODS: This retrospective study included 1,944 consecutive cases of LB performed between 2001 and 2018 in a tertiary hospital. All of the LBs were conducted under ultrasonography guidance with 18-gauge cutting needles | ||
520 | |a RESULTS: LBs were performed an average of approximately 108 times per year during the study period. Chronic hepatitis B (25.3%) and suspected malignancy (20.5%) were the two most common indications for LB. The use of LB for nonalcoholic fatty liver disease increased from 8.1% to 17.2% in the past 5 years compared to the last 10 years, while that for viral hepatitis decreased from 40.3% to 18.9%. Discordance rate between the suspected diagnosis and the final diagnosis was 2.6% (51 cases). The overall rate of major adverse events was 0.05% (one case), which involved delayed bleeding at the biopsy site. Liver cirrhosis was observed in 563 cases (28.9%), and the presence of cirrhosis did not affect the frequency of complications (P=0.289) | ||
520 | |a CONCLUSION: LB is widely used in clinical practice as an irreplaceable diagnostic tool, even in the era of noninvasiveness. Ultrasonography-guided LB can be performed safely in patients with liver cirrhosis | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Complication | |
650 | 4 | |a Indication | |
650 | 4 | |a Liver biopsy | |
700 | 1 | |a Kim, Jun Il |e verfasserin |4 aut | |
700 | 1 | |a Lee, Bora |e verfasserin |4 aut | |
700 | 1 | |a Kim, Sang Gyune |e verfasserin |4 aut | |
700 | 1 | |a Jung, Min Jung |e verfasserin |4 aut | |
700 | 1 | |a Kim, Young Seok |e verfasserin |4 aut | |
700 | 1 | |a Jeong, Soung Won |e verfasserin |4 aut | |
700 | 1 | |a Jang, Jae Young |e verfasserin |4 aut | |
700 | 1 | |a Yoo, Jeong-Ju |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical and molecular hepatology |d 2012 |g 26(2020), 3 vom: 25. Juli, Seite 318-327 |w (DE-627)NLM220236712 |x 2287-285X |7 nnns |
773 | 1 | 8 | |g volume:26 |g year:2020 |g number:3 |g day:25 |g month:07 |g pages:318-327 |
856 | 4 | 0 | |u http://dx.doi.org/10.3350/cmh.2019.0019n |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 26 |j 2020 |e 3 |b 25 |c 07 |h 318-327 |